Lipoprotein (a) and incident coronary heart disease in the community: impact of traditional cardiovascular risk factors - Takeaways - MDSpire

Lipoprotein (a) and incident coronary heart disease in the community: impact of traditional cardiovascular risk factors

  • By

  • Natalie Arnold

  • Alina Goßling

  • Benjamin Bay

  • Jessica Weimann

  • Christopher Blaum

  • Fabian J Brunner

  • Marco M Ferrario

  • Paolo Brambilla

  • Giancarlo Cesana

  • Valerio Leoni

  • Luigi Palmieri

  • Chiara Donfrancesco

  • Teresa Padró

  • Jonas Andersson

  • Pekka Jousilahti

  • Francisco Ojeda

  • Tanja Zeller

  • Allan Linneberg

  • Stefan Söderberg

  • Licia Iacoviello

  • Francesco Gianfagna

  • Susana Sans

  • Giovanni Veronesi

  • Barbara Thorand

  • Annette Peters

  • Hugh Tunstall-Pedoe

  • Frank Kee

  • Veikko Salomaa

  • Renate B Schnabel

  • Kari Kuulasmaa

  • Stefan Blankenberg

  • Christoph Waldeyer

  • Wolfgang Koenig

  • on behalf of the BiomarCARE investigators

  • June 12, 2025

  • 0 min

Share

  • 1

    High Lipoprotein (a) levels are associated with increased risk of coronary heart disease (CHD) regardless of traditional cardiovascular risk factors.

  • 2

    The study included 66,495 CHD-free individuals from eight European cohorts, stratified by the presence of cardiovascular risk factors.

  • 3

    Individuals with 0/1 cardiovascular risk factors showed a strong association between high Lp(a) and future CHD events.

  • 4

    The findings highlight challenges in managing Lp(a)-associated CHD risk in low-risk populations with few traditional risk factors.

  • 5

    Current strategies to mitigate high Lp(a) levels rely on reducing traditional cardiovascular risk factors, with new therapies under investigation.

Original Source(s)

Lipoprotein (a) and incident coronary heart disease in the community: impact of traditional cardiovascular risk factors

  • by Natalie Arnold, Alina Goßling, Benjamin Bay, Jessica Weimann, Christopher Blaum, Fabian J Brunner, Marco M Ferrario, Paolo Brambilla, Giancarlo Cesana, Valerio Leoni, Luigi Palmieri, Chiara Donfrancesco, Teresa Padró, Jonas Andersson, Pekka Jousilahti, Francisco Ojeda, Tanja Zeller, Allan Linneberg, Stefan Söderberg, Licia Iacoviello, Francesco Gianfagna, Susana Sans, Giovanni Veronesi, Barbara Thorand, Annette Peters, Hugh Tunstall-Pedoe, Frank Kee, Veikko Salomaa, Renate B Schnabel, Kari Kuulasmaa, Stefan Blankenberg, Christoph Waldeyer, Wolfgang Koenig, on behalf of the BiomarCARE investigators

  • June 12, 2025

Related Content

FDA Approves Baxdrostat for Resistant Hypertension

Phase 3 findings support the oral therapy in adults with persistent blood pressure elevation despite multidrug treatment.

Establishment and validation of a machine learning-based predictive model for in-hospital mortality risk in acute myocardial infarction patients complicated with diabetes mellitus

Association Between Metabolic Clusters and Microbial Age in High-Risk Populations for Diabetes and Their Potential Impact on Cardiovascular Disease Risk: Cross-Sectional Observational Study